A Phase I Study of HyperAcute-Renal (HAR) Immunotherapy In Patients With Metastatic Renal Cell Cancer
Latest Information Update: 07 Apr 2022
At a glance
- Drugs Renal cancer vaccine-NewLink Genetics (Primary)
- Indications Renal cancer
- Focus Adverse reactions; First in man
- Sponsors NewLink Genetics Corporation
- 04 Apr 2022 Status changed from active, no longer recruiting to completed.
- 01 Feb 2020 According to results published in the Oncologist, Hans Hammer and Neeraj Agarwal are the principal investigators of this study.
- 16 Feb 2019 Results presented at the 2019 Genitourinary Cancers Symposium